Prelude Therapeutics Files 8-K
Ticker: PRLD · Form: 8-K · Filed: Sep 19, 2025 · CIK: 1678660
Sentiment: neutral
Topics: 8-K, disclosure, other-event
TL;DR
Prelude Therapeutics filed an 8-K on 9/18/25. Details TBD.
AI Summary
On September 18, 2025, Prelude Therapeutics Incorporated announced an "Other Event" in a Form 8-K filing. The specific nature of this event is not detailed in the provided text, but it was filed on September 19, 2025, and pertains to the company's operations in Delaware.
Why It Matters
This filing indicates a material event has occurred for Prelude Therapeutics, requiring public disclosure. Investors should look for further details to understand the event's impact.
Risk Assessment
Risk Level: low — The filing itself is a standard disclosure and does not contain information that inherently increases risk.
Key Numbers
- 001-39527 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-1384762 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Prelude Therapeutics Incorporated (company) — Registrant
- September 18, 2025 (date) — Date of earliest event reported
- September 19, 2025 (date) — Date of report
- Delaware (location) — State of incorporation
- 175 Innovation Boulevard (address) — Principal executive offices
FAQ
What specific event is Prelude Therapeutics reporting in this 8-K filing?
The provided text states the filing is for an 'Other Event' but does not specify the nature of the event.
When was the earliest event reported in this filing?
The earliest event reported was on September 18, 2025.
On what date was this Form 8-K filed with the SEC?
The Form 8-K was filed on September 19, 2025.
In which state is Prelude Therapeutics Incorporated incorporated?
Prelude Therapeutics Incorporated is incorporated in Delaware.
What is the principal executive office address for Prelude Therapeutics?
The principal executive office is located at 175 Innovation Boulevard, Wilmington, Delaware, 19805.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2025-09-19 07:41:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PRLD Nasdaq Glo
- $1.00 — "Common Stock") had failed to meet the $1.00 per share Minimum Bid Price Requirement
Filing Documents
- prld-20250918.htm (8-K) — 44KB
- 0001193125-25-208187.txt ( ) — 178KB
- prld-20250918.xsd (EX-101.SCH) — 49KB
- prld-20250918_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events As previously disclosed on March 28, 2025, Prelude Therapeutics Incorporated (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 27, 2025, notifying the Company that it was not in compliance with the Nasdaq Minimum Bid Price Requirement because its common stock, par value $0.0001 per share (the "Common Stock") had failed to meet the $1.00 per share Minimum Bid Price Requirement. On September 18, 2025, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") and that the matter is now closed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: September 19, 2025 By: /s/ Bryant Lim Bryant Lim Chief Financial Officer